Prescient Therapeutics to present OmniCAR and CellPryme abstracts at international gene therapy conference
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) will present two of its abstracts at an annual...
The prestigious International Society of Cell and Gene Therapy (ISCT) will showcase two abstracts from Prescient...
ASX-listed clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has informed about the appointment of Dr...
Prescient Therapeutics Ltd (ASX:PTX) has strengthened its board through the appointment of experienced pharma executive Dr...
Prescient Therapeutics (ASX: PTX), the Australian listed entity into clinical stage oncology, has released its...
Life science stocks have suffered heavily in 2022 due to investors shifting out of risk...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has just presented at the Cell &...
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up...
Cell and gene therapy is changing the game when it comes to cancer treatment and...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.